Drug Profile
Hexasodium fytate - Sanifit
Alternative Names: Hexasodium phytate; Myo-inositol hexaphosphate; SNF-472Latest Information Update: 09 Nov 2022
Price :
$50
*
At a glance
- Originator Laboratoris Sanifit
- Developer CSL Vifor; Laboratoris Sanifit
- Class Antineoplastics; Calcium regulators; Cardiovascular therapies; Phosphates; Small molecules; Sodium compounds; Sugar alcohols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Calciphylaxis; Peripheral arterial disorders
Most Recent Events
- 09 Nov 2022 Phase-III clinical trials in Peripheral arterial disorders in USA (IV) (CSL Behring pipeline, November 2022)
- 24 Oct 2022 Sanifit Therapeutics completes a phase III trial in Calciphylaxis in Belgium, Poland, United Kingdom, Germany, Spain, USA (IV) (NCT04195906)
- 28 Sep 2022 Hexasodium fytate is still in phase III trials for Calciphylaxis in USA (IV) (NCT04195906)